WST

West Pharmaceutical Services, Inc. (WST) ESG Analysis Analysis (2026)

Invetso Score: 7.9/10 — Strong · Last Updated: 2026-10-01

Environmental

WST’s low debt intensity and modest R&D burden suggest a relatively disciplined capital base, which typically supports lower resource waste than more asset-heavy peers.

The company’s business model is less emissions-intensive than industrial and chemical peers, reducing exposure to carbon regulation and energy-cost volatility across the cycle.

No major environmental controversies were provided, and the available metrics do not indicate structurally elevated environmental risk versus peers.

Relative to peers, WST appears better positioned on operational efficiency than on explicit disclosure breadth, which limits evidence of top-tier environmental leadership.

Social

WST’s low stock-based compensation ratio suggests restrained dilution and a comparatively balanced approach to employee incentives versus peers with heavier equity compensation.

The absence of provided controversy indicators supports a cleaner social risk profile, which is favorable relative to peers facing recurring labor or product-safety issues.

As a healthcare packaging supplier, WST’s social exposure is mainly tied to product quality and customer trust, where peer expectations are high and failures can quickly damage reputation.

Relative to peers, the available data support a solid but not exceptional social profile because workforce and community disclosure depth is not evident here.

Governance

WST’s low debt-to-equity ratio indicates conservative balance-sheet governance, which reduces creditor pressure and lowers the likelihood of risk-taking versus leveraged peers.

Negative net debt to EBITDA suggests net cash-like flexibility, a governance strength that typically improves resilience and limits refinancing risk relative to peers.

Stock-based compensation remains modest, implying tighter capital discipline and less shareholder dilution than many peers with more aggressive incentive structures.

The available metrics point to disciplined governance, although the absence of board, audit, and shareholder-rights data prevents a top-tier score versus best-in-class peers.

Overall Score

WST screens as a strong ESG performer versus peers, led by conservative governance and a comparatively low environmental risk profile, with social disclosure limits tempering the score.

Score Driver: Conservative Balance-Sheet Governance

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on West Pharmaceutical Services, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →